[{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.28000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AEON Biopharma \/ PPD","highestDevelopmentStatusID":"14","companyTruncated":"AEON Biopharma \/ PPD"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AEON Biopharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by AEON Biopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target